Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alector Inc (ALEC)

Alector Inc (ALEC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 158,269
  • Shares Outstanding, K 109,151
  • Annual Sales, $ 100,560 K
  • Annual Income, $ -119,050 K
  • EBIT $ -124 M
  • EBITDA $ -129 M
  • 60-Month Beta 0.67
  • Price/Sales 1.53
  • Price/Cash Flow N/A
  • Price/Book 2.47

Options Overview Details

View History
  • Implied Volatility 442.18% (+144.08%)
  • Historical Volatility 71.10%
  • IV Percentile 90%
  • IV Rank 43.11%
  • IV High 905.32% on 11/13/25
  • IV Low 91.23% on 03/12/25
  • Expected Move (DTE 22) 0.3400 (23.45%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 539
  • Volume Avg (30-Day) 322
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 10,809
  • Open Int (30-Day) 16,914
  • Expected Range 1.1100 to 1.7900

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.41
  • Number of Estimates 4
  • High Estimate -0.34
  • Low Estimate -0.50
  • Prior Year -0.02
  • Growth Rate Est. (year over year) -1,950.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0900 +33.03%
on 12/03/25
1.5400 -5.84%
on 12/12/25
+0.1700 (+13.28%)
since 11/24/25
3-Month
1.0900 +33.03%
on 12/03/25
3.3999 -57.35%
on 10/16/25
-1.7100 (-54.11%)
since 09/24/25
52-Week
0.8700 +66.67%
on 04/09/25
3.3999 -57.35%
on 10/16/25
-0.4000 (-21.62%)
since 12/24/24

Most Recent Stories

More News
Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression...

ALEC : 1.4500 (+2.84%)
Alector to Participate in the Bank of America CNS Therapeutics Conference

SOUTH SAN FRANCISCO, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression...

ALEC : 1.4500 (+2.84%)
ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alector, Inc. (“Alector” or “the Company”) (NASDAQ:...

ALEC : 1.4500 (+2.84%)
Alector: Q3 Earnings Snapshot

Alector: Q3 Earnings Snapshot

ALEC : 1.4500 (+2.84%)
Alector Reports Third Quarter 2025 Financial Results and Provides Business Update

Selected lead candidates AL137 for the company’s Alector Brain Carrier (ABC)-enabled anti-amyloid beta antibody in Alzheimer's disease, and AL050 for its ABC-enabled GCase enzyme replacement therapy...

ALEC : 1.4500 (+2.84%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alector, Inc. - ALEC

NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Alector, Inc. ("Alector" or the "Company") (NASDAQ: ALEC). Such investors are advised to...

ALEC : 1.4500 (+2.84%)
ATTENTION Alector, Inc. (ALEC) Investors: Possible Fraud - Contact Levi & Korsinsky Today

New York, New York--(Newsfile Corp. - October 27, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Alector, Inc. ("Alector, Inc.") (NASDAQ: ALEC) concerning possible...

ALEC : 1.4500 (+2.84%)
Lost Money on Alector, Inc. (ALEC)? Contact Levi & Korsinsky About Investigation

New York, New York--(Newsfile Corp. - October 22, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Alector, Inc. ("Alector, Inc.") (NASDAQ: ALEC) concerning possible...

ALEC : 1.4500 (+2.84%)
Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression...

ALEC : 1.4500 (+2.84%)
Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs

SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating...

ALEC : 1.4500 (+2.84%)

Business Summary

Alector Inc. is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Its product portfolio includes AL001, AL101, Al002 and AL003 which are in clinical stage. Alector Inc. is headquartered in South San Francisco,...

See More

Key Turning Points

3rd Resistance Point 1.5233
2nd Resistance Point 1.4967
1st Resistance Point 1.4733
Last Price 1.4500
1st Support Level 1.4233
2nd Support Level 1.3967
3rd Support Level 1.3733

See More

52-Week High 3.3999
Fibonacci 61.8% 2.4335
Fibonacci 50% 2.1349
Fibonacci 38.2% 1.8364
Last Price 1.4500
52-Week Low 0.8700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar